

AMENDMENTS TO THE CLAIMS

Please amend the claims as indicated below:

1-29 (Cancelled).

30. (Previously presented) The method of Claim 41, wherein R_a is $-OR_1$.

31. (Previously presented) The method of Claim 41, wherein R_a is $-OCOR_1$.

32. (Currently amended) The method of Claim 41, wherein the ~~neovascularization~~ ocular angiogenesis is ocular neovascularization.

33. (Currently amended) The method of Claim 30, wherein the ~~neovascularization~~ ocular angiogenesis is ocular neovascularization.

34. (Currently amended) The method of Claim 31, wherein the ~~neovascularization~~ ocular angiogenesis is ocular neovascularization.

35. (Previously presented) The method of Claim 41, wherein the compound is 2-methoxyestradiol.

36. (Previously presented) The method of Claim 30, wherein the compound is 2-methoxyestradiol.


37. (Previously presented) The method of Claim 31, wherein the compound is 2-methoxyestradiol.

38. (Currently amended) The method of Claim 41, wherein the ~~neovascularization~~ ocular angiogenesis is ocular neovascularization and the compound is 2-methoxyestradiol.

39. (Currently amended) The method of Claim 30, wherein the ~~neovascularization~~ ocular angiogenesis is ocular neovascularization and the compound is 2-methoxyestradiol.

40. (Currently amended) The method of Claim 31, wherein the ~~neovascularization~~ ocular angiogenesis is ocular neovascularization and the compound is 2-methoxyestradiol.

41. (Currently amended) A method of ~~treating~~ inhibiting ocular angiogenesis ~~neovascularization~~ in a ~~mammal~~ human or an animal, comprising administering to the ~~mammal~~ human or animal a ~~neovascularization~~ an effective angiogenesis-inhibiting amount of a compound of the formula:



wherein, Ra is -R₁, -OR₁, -OCOR₁, -SR₁, -F, -NHR₂, -Br, or -I and wherein, in each formula set forth above, each R₁ and R₂ independently is -H, or a substituted or unsubstituted alkyl, alkenyl or alkynyl group of up to 6 carbons; and
provided that Ra is not H.